Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome (3 4-DAP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age 18 years or older,
Diagnosed with LEMS,
If female, have a negative pregnancy test, and
If premenopausal, be willing to practice an effective form of birth control during the study,
Tested and found by ECG not to have a prolonged QT syndrome,
Agree to have a second ECG at the time of peak drug effect,
Has understood and signed the Informed Consent.
Is known to have a sensitivity to 3, 4-DAP,
Has a history of:
past or current seizures,
hepatic, renal or hematologic disease, or
Is believed by the investigator to be unable to comply with the protocol.
Lambert-Eaton Myasthenic Syndrome Paraneoplastic Syndromes, Nervous System Paraneoplastic Syndromes
Nervous System Neoplasms
Neoplasms by Site
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Neuromuscular Junction Diseases
Immune System Diseases
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action